Three recent studies have shown that cost savings can be made by using the antibacterial clarithromycin to treat hospitalised patients with community-acquired pneumonia. The findings of these studies were presented at the 3rd International Conference on the Macrolides, Azalides and Streptogramins [Lisbon, Portugal; January 1996].